TP53 and colorectal carcinoma: Therefore, targeting Wt-p53, survivin, and miRNA-16-1 alone or together in CCSCs by a compound may provide lower toxicity to normal stem cells, as well as its differentiated progeny, and may open up avenues to new therapeutic strategies for CRC-directed therapy.